

Measles Technical Working Group: strategies for measles control and elimination

Report of a meeting, Geneva,
11-12 May 2000



**DEPARTMENT OF VACCINES
AND BIOLOGICALS**



*World Health Organization
Geneva
2001*

**The Department of Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This document was produced by the
Expanded Programme on Immunization
of the Department of Vaccines and Biologicals

This document is available only on the Internet at:
www.who.int/vaccines-documents/

World Health Organization
Department of Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2001

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The views expressed in documents by named authors are solely the responsibility of those authors.

Contents

<i>Abbreviations</i>	v
<i>Preface</i>	vii
Strategies for reducing global measles mortality	1
Recommendations from a meeting	1
Routine and supplementary immunization	3
Measles surveillance	4
Defining and monitoring measles elimination	5
Annex 1: List of participants	6

Abbreviations

AFP	acute flaccid paralysis
CDC	Centers for Disease Control and Prevention (USA)
EPI	Expanded Programme on Immunization
GAVI	Global Alliance for Vaccines and Immunization
NIDs	national immunization days
OPV	oral polio vaccine
UNICEF	United Nations Children's Fund
USAID	United States Agency for International Development
WHO	World Health Organization

Preface

In May 2000 WHO, UNICEF and the United States Centers for Disease Control and Prevention (CDC), cosponsored a meeting to bring together the representatives of international agencies, countries and academics with experience in measles control and elimination to review the strategies required to achieve measles mortality and morbidity reduction goals.

Participants reviewed the status of measles control and elimination and discussed and reviewed the global plan of action to establish milestones for measles control and elimination.

This report presents the recommendations of that meeting.

The recommendations of this meeting have also been published in Weekly Epidemiological Record, 15 December 2000, Vol. 75, 50 (pp 409-416).

Strategies for reducing global measles mortality

Recommendations from a meeting

Worldwide, measles vaccination has been very effective, preventing an estimated 80 million cases and 4.5 million deaths annually. Nevertheless, because vaccination coverage is not uniformly high, measles still causes approximately 30 million cases and 888 000 deaths each year – 40% of the estimated two million deaths caused annually by vaccine-preventable diseases of childhood. More than half of measles deaths occur in Africa.

The World Health Assembly in 1989 and the World Summit for Children in 1990 set goals for measles morbidity and mortality reduction of 90% and 95%, respectively, compared with prevaccine levels.¹ Subsequently, target dates for measles elimination in three WHO regions, the Americas, Europe and the Eastern Mediterranean, were set for 2000, 2007 and 2010, respectively.²

In May 2000, UNICEF and the United States Centers for Disease Control and Prevention (CDC) cosponsored a meeting of a technical working group³ to review the current status of global measles control and regional elimination efforts, and to formulate recommendations for accelerating control activities, particularly in countries and regions with a heavy burden of disease.

Meeting participants developed specific conclusions and recommendations concerning: action plans for accelerating measles control; improving routine and supplementary immunization; measles surveillance; defining and monitoring measles elimination; and providing vitamin A supplements to children at nutritional risk.

¹ World Health Assembly resolution WHA42.32.


² See No. 50, 1999, pp. 429-439.

³ Participants included country representatives and selected experts in measles control, representatives from each WHO regional office, UNICEF, the Japanese Agency for Cooperation in International Health, the International Federation of Red Cross and Red Crescent Societies, the World Bank, the United States Agency for International Development (USAID), the Public Health Laboratory Service of the United Kingdom, and the Centers for Disease Prevention and Control (United States).

After reviewing the epidemiological situation by region and in selected countries, participants agreed that very high immunization coverage is required to achieve a high level of measles control, and that a 1-dose measles policy is insufficient to achieve and sustain current measles control targets (Map 1). The average seroconversion rate of 85% following a single dose at age nine months, which is the recommended strategy for routine immunization in developing countries, leaves an important proportion of children susceptible. Furthermore, the routine delivery system in many countries has failed to reach many children with a dose at nine months.

- Action plans to reduce measles mortality through increasing immunization coverage should be part of each country's comprehensive long-term immunization strategy. Plans of action for measles mortality reduction should be incorporated into the 3-5 year Expanded Programme on Immunization (EPI) plans of action currently being developed or updated by countries.

Map 1: Reported routine measles vaccine coverage, 1999*



* From country reports to WHO as of 3 October 2000

The designations employed and the presentation of material on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area of its authorities, or concerning the delimitation of its frontiers or boundaries.

- Action plans should specify activities and budgets for all recommended strategies for measles control, including improving routine immunization, conducting supplementary immunization campaigns in both the short and long term, intensifying surveillance, managing measles cases, and providing vitamin A supplements.

-
- International development partner agencies and the Global Alliance for Vaccines and Immunization (GAVI)⁴ should advocate for global support to reduce measles mortality within the overall strengthening of immunization and support recommended strategies to reduce global measles mortality.
 - Until achieved, polio eradication should remain the top priority in all countries where wild poliovirus continues to circulate, or where acute flaccid paralysis (AFP) surveillance does not meet standards necessary to certify the eradication of wild poliovirus.⁵ Adding measles control to existing polio eradication activities should be done in a way which ensures the success of both goals, by maintaining focus on immunization and surveillance.

Routine and supplementary immunization

- Routine immunization is the foundation of effective measles control. Increasing and sustaining high routine measles coverage (i.e. over 90%) is essential for achieving sustainable reduction of measles mortality.
- Countries with support from partner agencies should assess the reasons for low coverage and strengthen efforts to improve routine immunization coverage using appropriate strategies (e.g. fixed posts, outreach services, door-to-door canvassing, and regular pulse immunization).⁶
- Management of immunization services must be strengthened at all levels. WHO and UNICEF should guide and support the development of training courses and tools that cover such topics as reducing missed opportunities and drop-out rates,⁷ canvassing door to door, conducting outreach and periodic supplementary campaigns.
- Training and supervision of immunization safety must be given high priority so as to ensure proper handling and reconstitution of the vaccine, appropriate injection techniques, safe disposal of syringes and needles, and the monitoring of adverse events.
- In addition to the first dose at age nine months, countries should provide children a second opportunity for measles vaccination. The second opportunity provides a first dose of vaccine to children previously missed by routine services or a second dose to children who failed to respond to their first dose. The second opportunity can be provided through supplementary campaigns, routine immunization services,⁸ or a combination.

⁴ For details see <http://www.vaccinealliance.org>.

⁵ See No. 17, 2000, pp. 134-143.

⁶ Periodic vaccination campaigns, usually conducted within a limited geographical area such as a district, targeting all children born since the last campaign.

⁷ Usually calculated as the difference in vaccination coverage between the first and third doses of combined diphtheria-tetanus-pertussis vaccine.

⁸ In countries with highly developed immunization programmes capable of achieving and sustaining measles immunization coverage exceeding 90% through routine services, the second opportunity for measles immunization can also be provided through the implementation of a routine 2-dose vaccination schedule.

-
- Mass measles vaccination campaigns, if well implemented, are an effective strategy to control measles. Campaigns will result in a period when measles transmission is low or absent. The impact of campaigns is more prolonged when they are conducted in settings where routine coverage is high or improving. Depending on the coverage achieved in the campaign and the routine vaccination coverage, campaigns will need to be repeated at regular intervals.
 - Campaigns should target large populations (entire nations or large regions) and achieve high coverage (>90%) with quality services. Preliminary data from the WHO African Region suggest that targeted urban campaigns have limited impact on measles transmission either in cities or in neighbouring rural areas.
 - The target age group for mass campaigns should be based on the susceptibility profile of the population, which can be determined from the history of measles vaccination coverage, age-specific disease incidence data, and seroprevalence studies. Campaigns should include special efforts to reach previously unvaccinated children. Planning for measles campaigns should take into account the need for improvements in routine services.
 - Most intensified oral polio vaccine (OPV) immunization activities are now conducted in polio priority countries with the weakest health infrastructure and usually on a house-to-house basis. In general, it is not appropriate to add measles vaccine to house-to-house OPV immunization activities. Adding measles to polio national immunization days (NIDs) should only be considered if there is sufficient time for planning, sufficient funding, adequate logistical preparation, adequate supervision and monitoring, and ensured injection safety.
 - Mass campaigns have to be planned carefully, with particular attention to the immunization safety component, so that sufficient trained personnel, syringes, needles and vaccines will be available. All countries implementing mass measles campaigns should ensure appropriate management through a plan that includes an adequate budget, the use of monitoring tools (e.g. a supervision checklist) during implementation, and the assessment of waste management.
 - Mass campaigns should include an assessment component in order to improve future measles mortality reduction activities. All countries undertaking mass campaigns should document immunization safety during campaigns and routine services, using recommended assessment tools. Assessment should include reviewing coverage trends before and after campaigns.

Measles surveillance

- Where feasible and appropriate, surveillance for measles should be integrated into existing surveillance for acute flaccid paralysis. However, measles surveillance must be carefully adapted to country capacities and must not overburden AFP surveillance capacity.
- Measles surveillance should collect the basic information to document disease burden and guide programme planning: measles case counts by month and geographical area (both urban and rural); age and vaccination status of cases by area; and timeliness and completeness of reporting.

-
- Surveillance information should be reported and analysed regularly at all levels (e.g. weekly or monthly). Feedback of this information is critical for maintaining the surveillance system and guiding control efforts.
 - Countries should use outbreak investigations and sentinel surveillance as additional opportunities to monitor changes in measles epidemiology (e.g. age distribution and vaccination status of cases and case-fatality rates).

In addition, the following strategies should be implemented to achieve further reduction of overall mortality among children aged < 5 years.

- In countries where vitamin A deficiency is a significant public health problem, provision of vitamin A supplements to children aged six months to five years every 4-6 months through immunization contacts as appropriate:
 - vitamin A supplements should be provided with routine measles vaccination (usually at age nine months);
 - measles campaigns and response to measles outbreaks should be used as an opportunity to provide vitamin A to those children at risk of measles, regardless of immunization history.
- Improved management of measles cases including vitamin A supplementation and adequate treatment of complications.

Defining and monitoring measles elimination

- Measles elimination is defined as the absence of ongoing transmission of the measles virus in a large geographical area. When elimination has been achieved, imported cases may still occur, with limited spread to susceptible persons. Therefore elimination does not equate to zero cases.
- Proposed methods for monitoring elimination of indigenous transmission of measles virus (using proportion of cases imported and distribution of outbreak sizes and duration) should be applied in different countries and regional settings to further assess their usefulness.
- Special studies of susceptibility patterns (e.g. seroprevalence studies and disease modelling) may be useful in projecting the likelihood of transmission of measles and determining the target age groups for supplementary vaccination.

A strategic plan for global measles mortality reduction and regional elimination for 2001–2005 that includes these recommendations and conclusions will be published by WHO/UNICEF in 2001.

Annex 1:

List of participants

Temporary advisers

Dr (Mrs) Swati Y. Bhawe, President, Consulting Pediatrician,
Bombay Hospital & Medical Research Center, 1st floor New Wing,
New Marine Lines, Mumbai 400 020, India.

Tel: +91 22 206 7676 Ext. 434; Fax: +91 22 201 5557

Email: sbhave@bom7.vsnl.net.in

Prof. Felicity Cutts, London School of Hygiene , and Tropical Medicine,
Infectious Disease Epidemiology Unit, Keppel Street, GB-London WC1E 7HT,
United Kingdom.

Tel: +44 20 7927 2209; Fax: +44 20 7436 4230

Email: fcutts@lshtm.ac.uk

Dr John Edmunds, Public Health Laboratory Service (PHLS),
Communicable Diseases Surveillance Centre, 61 Colindale Avenue,
GB-London NW9 5EQ, United Kingdom.

Tel.: +44 20 8200 6868 Ext. 4410; Fax: +44 20 8200 7868

Email: jedmunds@phls.nhs.uk

Dr David Brown, Public Health Laboratory Service (PHLS),
Communicable Disease Surveillance Centre, 61 Colindale Avenue,
GB-London Nw9 5EQ, United Kingdom

Tel: +44 20 8200 6868; Fax: +44 20 8200 8195

Email: dbrown@phl.nhs.uk

Dr John Edmunds, Public Health Laboratory(PHLS),
Communicable Disease Surveillance Centre, 61 Colindale Avenue,
GB-London Nw9 5EQ, United Kingdom

Tel: +44 20 8200 6868; Fax: +44 20 8200 7868

Email: edmunds@phls.nhs.uk

Dr Stanley Foster, Department of International Health,
Rollins School of Public Health at Emory University , 1518 Clifton Road,
Atlanta, GA 30322, USA

Tel: +1 404 727 8804; Fax: +1 404 727 4590

Email: sfoster@sph.emory.edu

Mr Nigel J. Gay, Public Health Laboratory Service (PHLS),
Communicable Disease Surveillance Centre, 61 Colindale Avenue,
GB-London Nw9 5EQ, United Kingdom
Tel: +44 20 8200 6868; Fax: +44 20 8200 7868
Email: ngay@phls.nhs.uk

Prof. Peter Ndumbe, University of Yaoundé, Centre for the Study and Control of
Communicable Diseases, Faculty of Medicine and Biomedical Sciences,
B.P. 8445, Yaoundé, Cameroon
Tel: +237 31 51 04; Fax: +237 31 51 78
Email: camdiagnostix@camnet.cm

Prof. Francis Nkrumah, Noguchi Memorial Institute for Medical Research ,
University of Ghana, P.O. Box 25 Legon, Ghana
Tel: +233 21 50 11 80; Fax: +233 21 502 182
Email: fnkrumah@noguchi.mimcom.net

Dr David Salisbury, Principal Medical Officer, Department of Health,
Wellington House, Room 707, 133 – 155 Waterloo Road,
GB-London SE1 8UG, United Kingdom
Tel: +44 171 972 4488; Fax: +44 171 972 4468
Email: dsalisbu@doh.gov.uk

Dr Peter Wright, Vanderbilt University, Department of Paediatrics,
Division of Infectious Disease, 1161 21st Avenue Nashville T,
N 37232-2581, USA
Tel: +1 615 322 2477; Fax: +1 615 343 9723
Email: peter.wright@mcmail.vanderbilt

Partners

Agency for Cooperation in International Health

Dr Isao Arita
Chairman, Agency for Cooperation in International Health,
4-11-1 Higashi-machi, Kumamoto City, Kumamoto 862 0901, Japan
Tel: +81 96 367 8899; Fax: +81 96 367 9001
Email: acih@msa.biglobe.ne.jp

BASICS II

Mr Robert Steinglass, 1600 Wilson Boulevard, Suite 300, Arlington,
VA 22209, USA
Tel: +1 703 312 6800; Fax: +1 703 312 6900
Email: rsteingl@basics.org

Centers for Disease Control and Prevention (CDC)

1600 Clifton Road (E05), Atlanta, GA 30333, USA

Tel: +1 404 639 8252/8764; Fax: +1 404 639 8573

Dr Steve Cochi

Email: slc1@cdc.gov

Dr Walter Orenstein

Email: wao1@nip.em.cdc.gov

Dr Peter Strebel

Email: pms4@cdc.gov

Dr Roland Sutter

Email: rws4@cdc.gov

Mr Robert Keegan

Email: rak1@cdc.gov

Dr Mark Papania

Email: mpapania@cdc.gov

Dr Dalya Guris

Email: dhm5@cdc.gov

Dr Paul Rota

Institut Pasteur (Reseau International)

Dr Colette Roure, 28 rue de Roux, F-75724 Paris, Cedex 15, France

Tel: +33 1 40 61 39 42

Email: dgreseau@pasteur.fr

International Federation of Red Cross and Red Crescent Societies (IFRC)

Dr Bradley Hersh, PO Box 372, CH-1211 Geneva 19, Switzerland

Tel: +41 22 730 4340; Fax: +41 22 733 0395

Email: hersh@ifrc.org

World Bank

Dr Alan Hinman, Senior Consultant, CDC/World Bank Collaboration on Immunization, Task Force for Child Survival and Development,

750 Commerce Drive, Suite 400, Decatur, GA 30030-2612, USA

Tel: +1 404 687 5636; Fax: +1 404 371 0415

Email: ahinman@taskforce.org

United Nations Children's Fund (UNICEF)

Dr Edward Hoekstra, UNICEF, 3 United Nations Plaza,
New York, NY 10017, USA

Tel: +1 212 824 6464; Fax: +1 212 824 6464

Email: ehoekstra@unicef.org

Dr Alex Malyavin, UNICEF Regional office for CEE/CIS & Baltics

Tel: +1 212 824 6563; Fax: +1 212 824 6460

Email: Alexander_Malyavin_at_PO576A01@smtplink.unicef.org

Bob Davis, 3 United Nations Plaza, TA 24A, New York, NY 10017, USA

Fax: +1 212 824 6464

Email: rdavis@unicef.org

Dr Jean Michel Ndiaye, Regional Advisor/Health, UNICEF,
Immeuble Alliance 11 04, B.P. 443, Abidjan, 04, Côte d'Ivoire

Tel: +225 213 131

Email: mjndiaye@unicef.org

United States Agency for International Development (USAID)

Ronald Reagan Building, Washington, D.C. 20523-3700, USA

Dr Murray Trostle, Senior Public Health Advisor, G/PHN/HN/CSD, 3rd floor,

Fax: +1 202 216 3702

Email: mtrostle@usaid.gov

Ms Ellyn Ogden, Senior Technical Advisor for Child Survival ,
& World Wide Polio Eradication Coordinator

Fax: +1 202 216 3702

Email: eogden@usaid.gov

Countries (defined by the regional offices)

Dr Daniela Pitigoi, Director of Prevention Department, Ministry of Health,
Str. Ministerului 2-4, R-70052 Bucharest, Romania

Tel: +401 313 1452; Fax: +401 310 0542

Dr Olga Viktorovna, Head of Surveillance Department Republic Centre of
Immunoprophylaxis, C/o D rAlmaz S. Imanbaev, WHO Liaison Officer,
WHO Information Central Asian Republics Toktogoul str. 62,
720021 Bishkek, Kyrgyzstan

Fax: +966 312 293 593

Dr Ali Jaffer Mohammad, Director General of Health Affairs,
Sultanate of Oman, Ministry of Health Muscat, Oman

Tel: +968 202 177; Fax: +968 696 099

WHO Secretariat

Regional offices

Regional Office for Africa (AFRO)

Parirenyatwa Hospital, P.O. Box BE 773, Harare, Zimbabwe

Tel: +263 470 6951/7493; Fax: +263 479 1214

Dr Okwo Bele

Dr Amadou Fall

Dr Mac Otten

Dr Mark Grabowski, WHO/Uganda

Dr Rudi Eggers, WHO/Kenya

Dr Deo Nshimirimana, WHO/Côte d'Ivoire

Dr O Babanyi, WHO/Zimbabwe

Dr R. Adegbinni, WHO/ Zimbabwe

Dr Julie Rasoarimala, WHO/Cameroon

Dr M. Kamwa, DRC Team Leader

Dr R. Gama, Angola Team leader

Mr Z. Cuddy, WHO/Côte d'Ivoire

Regional Office for the Americas/Pan American Sanitary Bureau (AMRO/PAHO)

525 23rd Street, N.W., Washington, D.C. 200037, USA

Tel: +1 202 974 3247; Fax: +1 202 974 3635

Dr Ciro A de Quadros

Regional Office for the Eastern Mediterranean (EMRO)

P.O. Box 1517, Alexandria – 21511, Egypt

Tel: +203 48 33 285; Fax: +203 48 33 285

Dr Taky Gaafar

Dr M.H. Wadhan

Dr H. Jafari

Dr Ester de Gourville

Dr Faten Kamel

Regional Office for Europe (EURO)

8, Scherfigsvej, DK-2100 Copenhagen, Denmark

Tel: +45 39 17 15 34; Fax: +45 39 17 18 18

Dr Steve Wassilak

Dr G. Oblapenko

Dr Galina Lypskaya

Regional Office for South-East Asia (SEARO)

World House, Indraprastha Estate, Mahatma Ghandhi Road,
New Delhi 110002, India

Tel: +91 11 311 7804; Fax: +91 11 335 2106

Dr Palitha Abeykoon, Director, HTP

Dr Jon Andrus

Dr Arun Thapa

Dr Fitzsimmons

Dr Reza Hossani

Regional Office for the Western Pacific (WPRO)

P.O. Box 2932, 1099 Manila, Philippines

Tel: +632 522 9970; Fax: +632 52 11 036

Mr Chris Maher

Dr Jeff McFarland

Dr Yang Boaping, WPRO/Lao People's Democratic Republic

WHO headquarters

20 avenue Appia, CH-1211 Geneva 27, Switzerland

Tel: +41 22 791 2111; Fax: +41 22 791 0746

Health Technology and Pharmaceuticals (HTP) cluster

Department of Vaccines and Biologicals (V&B)

Dr Bjorn Melgaard, Director, V&B

Dr Maria Teresa Aguado, Coordinator, Vaccine Development (VAD), V&B

Dr Bruce Aylward, Global Polio Coordinator

Dr Maureen Birmingham, Coordinator, Vaccine Assessment and Monitoring
(VAM), V&B

Dr John Clements, Expanded Programme on Immunization (EPI), V&B

Dr Philippe Duclos, Vaccine Assessment and Monitoring (VAM), V&B

Mr David Featherstone, VAM/V&B

Ms Carole Francis, EPI/V&B

Ms Tracey Goodman, EPI/V&B

Dr Elwyn Griffiths, Coordinator, Quality and Safety of Biologicals (QSB), V&B

Dr Ana Maria Henao-Restrepo, EPI/V&B

Ms Rachel Horner, VAM/V&B

Dr Harry Hull, EPI/V&B

Ms Jennifer Linkins, EPI/V&B

Ms Gill Mayers, EPI/V&B

Dr Julie Milstien, Coordinator, Access to Technology (ATT), V&B

Dr Jean-Marc Olivé, EPI/V&B

Dr Yuri Pervikov, VAD/V&B

Dr Rudi Tangermann, EPI/V&B

Dr Jay Wenger, EPI/V&B

Mr Michel Zaffran, Programme Manager, V&B

Other WHO clusters

Evidence and Information for Policy (EIP)

Dr Prabhat Jha, Department of Research Policy and Cooperation (RPC)

Dr David Evans, Department of Research Policy and Cooperation (RPC)

Dr Jorn Heldrup, Department of Organization of Health Services Delivery (OSD)

Communicable Diseases (CDS)

Dr Michael Ryan, Integrated Surveillance and Response (ISR),

Department of Communicable Disease Surveillance and Response (CSR)

Dr Maria Neira, Strategy Development and Monitoring for Eradication and

Elimination (CEE), Department of Communicable Disease Control,

Prevention and Eradication (CPE)